| Literature DB >> 29220509 |
Massimiliano Zanin1, Ivan Chorbev2, Blaz Stres3, Egils Stalidzans4, Julio Vera5, Paolo Tieri6, Filippo Castiglione7, Derek Groen8, Huiru Zheng9, Jan Baumbach10, Johannes A Schmid11, José Basilio12, Peter Klimek13, Nataša Debeljak14, Damjana Rozman14, Harald H H W Schmidt15.
Abstract
Systems medicine holds many promises, but has so far provided only a limited number of proofs of principle. To address this road block, possible barriers and challenges of translating systems medicine into clinical practice need to be identified and addressed. The members of the European Cooperation in Science and Technology (COST) Action CA15120 Open Multiscale Systems Medicine (OpenMultiMed) wish to engage the scientific community of systems medicine and multiscale modelling, data science and computing, to provide their feedback in a structured manner. This will result in follow-up white papers and open access resources to accelerate the clinical translation of systems medicine.Entities:
Keywords: computing; data science; modelling; systems medicine
Mesh:
Year: 2019 PMID: 29220509 PMCID: PMC6135236 DOI: 10.1093/bib/bbx160
Source DB: PubMed Journal: Brief Bioinform ISSN: 1467-5463 Impact factor: 11.622
Access to the four questionnaires—also available through the OpenMultiMed Web portal [3]
| Topic | Questionnaire URL |
|---|---|
| Systems medicine |
|
| Multiscale modelling |
|
| Multiscale data science |
|
| Multiscale computing |
|
Figure 1Illustration of a systems medicine workflow: (A) multidimensional data comprising molecular information (gene expression, proteins, lipids, metabolites, etc.) for a large group of individuals as well as clinical parameters or biomarkers (plotted in a three-dimensional format with Mathematica); (B) example of visualization of multiple factors or biomarkers by a multi-parallel coordinate plot—adapted from [14] with permission from Wiley Online (e.g. patients with thrombotic diseases). Each arrow from 1 to 10 represents a biomarker, a clinical or a molecular parameter and is plotted in arbitrary units on a separate y-axis. Each patient represents a line linking the values of all the parameters (1–10). Data from numerous patients result in a high-density bundle of lines, which are represented in a pseudocolor mode to visualize their frequencies. In this example, the parameters of a single patient are shown as black line implying that the individual falls within the subgroup of stroke patients, although the person did not present with clear symptoms of stroke. The second major subgroup represents myocardial infarction, as indicated. (C) Molecular data from comorbidities can be used to calculate disease networks to identify nodes and hubs as promising targets for drug combination strategies and precision medicine.